Retinal Vein Occlusion News and Research

RSS
Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the elderly or middle-aged, it causes a subacute loss of vision.
Allergan third quarter diluted loss per share increases to $2.21

Allergan third quarter diluted loss per share increases to $2.21

FDA approves OZURDEX implant for uveitis treatment

FDA approves OZURDEX implant for uveitis treatment

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter

PDL BioPharma reports revenue guidance of $86 million for 2010 third quarter

Allergan second-quarter diluted EPS increases to $0.78

Allergan second-quarter diluted EPS increases to $0.78

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Winners of BioMed Central Annual Research Awards announced

Winners of BioMed Central Annual Research Awards announced

Report shows increasing rates of AMD among Asians

Report shows increasing rates of AMD among Asians

REGN reports net loss of $30.5M for first-quarter 2010

REGN reports net loss of $30.5M for first-quarter 2010

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Genentech announces two Phase III study results of Lucentis

Genentech announces two Phase III study results of Lucentis

Fovea Pharmaceuticals to sell 100% of its share to Sanofi-Aventis

Fovea Pharmaceuticals to sell 100% of its share to Sanofi-Aventis

Enrollment for pSivida's pilot FAVOR clinical study commences

Enrollment for pSivida's pilot FAVOR clinical study commences

Alimera Sciences starts pilot study of Iluvien intravitreal insert

Alimera Sciences starts pilot study of Iluvien intravitreal insert

Triamcinolone may be a treatment option for some patients with retinal vein occlusion

Triamcinolone may be a treatment option for some patients with retinal vein occlusion

Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed

Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed

Aston Academy investigates macular oedema

Aston Academy investigates macular oedema

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.